Targeting Akt in cell transfer immunotherapy for cancer. (1st September 2016)

• Record Type: Journal Article
• Authors: Crompton, Joseph G; Sukumar, Madhusudhanan; Restifo, Nicholas P
• Is Part Of: Oncoimmunology. Volume 5:Number 9(2016)
• Publication Date: 2016-09-01
• Subjects: Akt inhibition -- cell-based immunotherapy -- immunometabolism; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2015.1014776
• Languages: English
• ISSNs: 2162-402X

Abstract

Abstract : Pharmacologic inhibitors of the serine/threonine kinase Akt, initially aimed at deranged oncogenic pathways in tumors, have recently been shown to act as immunomodulators that markedly enhance the antitumor properties of T cells. Repurposing Akt inhibitors to improve antitumor immunity may be viewed as a manifestation of a larger paradigmatic shift in which hallmark characteristics of cancer (e.g., immune evasion), rather than merely causal features (e.g., somatic mutations) can be exploited for therapeutic benefit.